Si-Yang Liu, MD, Guangdong Lung Cancer Institute, Guangzhou, China, discusses findings from a Phase II trial (NCT04015778) of neoadjuvant nivolumab with or without platinum-doublet chemotherapy in patients with non-small cell lung cancer (NSCLC) based on PD-L1 status. Major pathologic response and pathologic complete response were the primary and secondary endpoints respectively. Combining chemotherapy with existing neoadjuvant immunotherapy benefited all patients and ctDNA clearance was additionally found to be a promising predictor of response. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
